Abstract
Celastrol, a plant triterpene has attracted great interest recently, especially for its potential anti-inflammatory and anti-cancer activities. In the present report, we investigated the effect of celastrol on proliferation of various cancer cell lines. The mechanism, by which this triterpene exerts its apoptotic effects, was also examined in detail. We found that celastrol inhibited the proliferation of wide variety of human tumor cell types including multiple myeloma, hepatocellular carcinoma, gastric cancer, prostate cancer, renal cell carcinoma, head and neck carcinoma, non-small cell lung carcinoma, melanoma, glioma, and breast cancer with concentrations as low as 1 μM. Growth inhibitory effects of celastrol correlated with a decrease in the levels of cyclin D1 and cyclin E, but concomitant increase in the levels of p21 and p27. The apoptosis induced by celastrol was indicated by the activation of caspase-8, bid cleavage, caspase-9 activation, caspase-3 activation, PARP cleavage and through the down regulation of anti-apoptototic proteins. The apoptotic effects of celastrol were preceded by activation of JNK and down-regulation of Akt activation. JNK was needed for celastrol-induced apoptosis, and inhibition of JNK by pharmacological inhibitor abolished the apoptotic effects. Overall, our results indicate that celastrol can inhibit cell proliferation and induce apoptosis through the activation of JNK, suppression of Akt, and down-regulation of anti-apoptotic protein expression.
Similar content being viewed by others
Abbreviations
- NF-κB:
-
Nuclear factor-kappa B
- FBS:
-
Fetal bovine serum
- GSK3β:
-
Glycogen synthase kinase 3 beta
- SDS:
-
Sodium dodecyl sulfate
- TUNEL:
-
Terminal deoxyuridine triphosphate nick end-labeling
- JNK:
-
c-Jun N-terminal kinase
- PARP:
-
Poly (ADP-ribose) polymerase
- PI3K:
-
Phosphoinositide 3-kinase
- PDK1:
-
3-phosphoinositide-dependent protein kinase-1
- VEGF:
-
Vascular endothelial growth factor
- XIAP:
-
X-linked inhibitor of apoptosis
References
Gupta SC, Kim JH, Prasad S, Aggarwal BB (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29:405–434
Gullett NP, Ruhul Amin AR, Bayraktar S et al (2010) Cancer prevention with natural compounds. Semin Oncol 37:258–281
Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C (2001) Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 25:1341–1357
Kim DY, Park JW, Jeoung D, Ro JY (2009) Celastrol suppresses allergen-induced airway inflammation in a mouse allergic asthma model. Eur J Pharmacol 612:98–105
Salminen A, Lehtonen M, Paimela T, Kaarniranta K (2010) Celastrol: molecular targets of Thunder God Vine. Biochem Biophys Res Commun 394:439–442
Morita T (2010) Celastrol: a new therapeutic potential of traditional Chinese medicine. Am J Hypertens 23:821
Kannaiyan R, Shanmugam MK, Sethi G (2011) Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 303:9–20
Yang H, Chen D, Cui QC, Yuan X, Dou QP (2006) Celastrol, a triterpene extracted from the Chinese “Thunder of God Vine,” is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66:4758–4765
Lu Z, Jin Y, Qiu L, Lai Y, Pan J (2010) Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett 290:182–191
Sung B, Park B, Yadav VR, Aggarwal BB (2010) Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem 285:11498–11507
Pang X, Yi Z, Zhang J et al (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 70:1951–1959
Yadav VR, Sung B, Prasad S et al (2010) Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med 88:1243–1253
Raja SM, Clubb RJ, Ortega-Cava C et al (2011) Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther 11:263–276
Lee JH, Koo TH, Yoon H et al (2006) Inhibition of NF-κB activation through targeting IκB kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 72:1311–1321
Sethi G, Ahn KS, Pandey MK, Aggarwal BB (2007) Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109:2727–2735
He D, Xu Q, Yan M et al (2009) The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 9:343
Sethi G, Tergaonkar V (2009) Potential pharmacological control of the NF-κB pathway. Trends Pharmacol Sci 30:313–321
Li F, Sethi G (2010) Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805:167–180
Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, Sakato N (2003) Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 67:1883–1887
Li-Weber M (2010) Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. (Epub ahead of print)
Ashkenazi S, Cleary TG (1990) A method for detecting Shiga toxin and Shiga-like toxin-I in pure and mixed culture. J Med Microbiol 32:255–261
Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM (1999) Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 274:5053–5060
Reed JC (2003) Apoptosis-targeted therapies for cancer. Cancer Cell 3:17–22
Russo M, Mupo A, Spagnuolo C, Russo GL (2010) Exploring death receptor pathways as selective targets in cancer therapy. Biochem Pharmacol 80:674–682
Strasser A, O’Connor L, Dixit VM (2000) Apoptosis signaling. Annu Rev Biochem 69:217–245
Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1:111–121
Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297–309
Varfolomeev EE, Ashkenazi A (2004) Tumor necrosis factor: an apoptosis JuNKie? Cell 116:491–497
Johnson GL, Nakamura K (2007) The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta 1773:1341–1348
de Vente JE, Kukoly CA, Bryant WO et al (1995) Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J Clin Invest 96:1874–1886
Papa S, Bubici C, Zazzeroni F et al (2006) The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ 13:712–729
Rajendran P, Ong TH, Chen L et al (2011) Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 17:1425–1439
Li F, Rajendran P, Sethi G (2010) Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol 161:541–554
Kumar AP, Quake AL, Chang MK et al (2009) Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. Cancer Res 69:8636–8644
Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G (2010) Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 334:285–293
Matsushime H, Roussel MF, Ashmun RA, Sherr CJ (1991) Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65:701–713
Enoch T, Nurse P (1990) Mutation of fission yeast cell cycle control genes abolishes dependence of mitosis on DNA replication. Cell 60:665–673
Koff A, Giordano A, Desai D et al (1992) Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257:1689–1694
Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G (2007) Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 73:1024–1032
Aprelikova O, Xiong Y, Liu ET (1995) Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 270:18195–18197
Alessandrini A, Chiaur DS, Pagano M (1997) Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11:342–345
Luo Y, Hurwitz J, Massague J (1995) Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375:159–161
Zhu L, Fukuda S, Cordis G, Das DK, Maulik N (2001) Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett 508:369–374
Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J (1998) Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 188:211–216
Catz SD, Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20:7342–7351
Kreuz S, Siegmund D, Scheurich P, Wajant H (2001) NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 21:3964–3973
Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB (2002) Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23:143–150
Hakem R, Hakem A, Duncan GS et al (1998) Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94:339–352
Marte BM, Downward J (1997) PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 22:355–358
Luo J, Manning BD, Cantley LC (2003) Targeting the PI3 K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4:257–262
Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261–1274
Ihle NT, Powis G (2009) Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 8:1–9
Liu J, Lin A (2005) Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15:36–42
Dhanasekaran DN, Reddy EP (2008) JNK signaling in apoptosis. Oncogene 27:6245–6251
Kim JK, Diehl JA (2009) Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 220:292–296
Yang HS, Kim JY, Lee JH et al (2011) Celastrol isolated from Tripterygium regelii induces apoptosis through both caspase-dependent and -independent pathways in human breast cancer cells. Food Chem Toxicol 49:527–532
Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM (1998) An induced proximity model for caspase-8 activation. J Biol Chem 273:2926–2930
Fulda S (2009) Caspase-8 in cancer biology and therapy. Cancer Lett 281:128–133
Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657
Deng Y, Ren X, Yang L, Lin Y, Wu X (2003) A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 115:61–70
Le-Niculescu H, Bonfoco E, Kasuya Y, Claret FX, Green DR, Karin M (1999) Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol Cell Biol 19:751–763
Herr I, Wilhelm D, Meyer E, Jeremias I, Angel P, Debatin KM (1999) JNK/SAPK activity contributes to TRAIL-induced apoptosis. Cell Death Differ 6:130–135
Vivo C, Liu W, Broaddus VC (2003) c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 278:25461–25467
Koo MS, Kwo YG, Park JH, Choi WJ, Billiar TR, Kim YM (2002) Signaling and function of caspase and c-jun N-terminal kinase in cisplatin-induced apoptosis. Mol Cells 13:194–201
Acknowledgments
This work was supported by grants from National Medical Research Council of Singapore (Grant R-184-000-201-275), Academic Research Fund (Grant R-184-000-177-112) and National Kidney Foundation (Grant R-184-000-196-592) to GS. APK was supported by grants from the National Medical Research Council of Singapore (Grant R-713-000-124-213) and Cancer Science Institute of Singapore, Experimental Therapeutics I Program (Grant R-713-001-011-271).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Radhamani Kannaiyan and Kanjoormana Aryan Manu contributed equally to this study.
Rights and permissions
About this article
Cite this article
Kannaiyan, R., Manu, K.A., Chen, L. et al. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis 16, 1028–1041 (2011). https://doi.org/10.1007/s10495-011-0629-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10495-011-0629-6